2022年12月至2023年2月奥密克戎变异株流行期间癌症患者中新型冠状病毒肺炎感染的临床特征及预后因素
Clinical characteristics and prognostic factors of COVID-19 infection among cancer patients during the December 2022 - February 2023 Omicron variant outbreak.
作者信息
Liu Li-Li, Liao Yu-Wei, Yu Xiao-Hua, Rong Ling, Chen Bi-Gui, Chen Gang, Zeng Guang-Kuan, Yang Li-Ye
机构信息
Precision Medical Laboratory Center, People's Hospital of Yangjiang Affiliated to Guangdong Medical University, Yangjiang, Guangdong, China.
Key Laboratory of Respiratory Disease of Yangjiang, People's Hospital of Yangjiang Affiliated to Guangdong Medical University, Yangjiang, Guangdong, China.
出版信息
Front Med (Lausanne). 2024 May 30;11:1401439. doi: 10.3389/fmed.2024.1401439. eCollection 2024.
OBJECTIVE
To analyze the clinical characteristics and prognostic impacts of SARS-CoV-2 Omicron infection among cancer inpatients during the December 2022 - February 2023 surge, in order to provide scientific evidence for clinical treatment and prevention and control measures.
METHODS
A retrospective analysis was conducted on the clinical features, prognosis, and vaccination status of cancer in-patients infected with the Omicron variant during the COVID-19 pandemic of December 2022 - February 2023.
RESULTS
A total of 137 cancer inpatients were included in the study, with a median age of 61 years, and 75 patients (54.74%) were male. The main symptoms were cough (69 cases, 50.36%), expectoration (60 cases, 43.80%), and fever (53 cases, 39.69%). Chest CT examination revealed bilateral pneumonia in 47 cases (34.31%, 47/137) and pleural effusion in 24 cases (17.52%, 24/137). Among the cancer patients, 116 cases (84.67%, 116/137) had solid tumors, and 21 cases (15.33%, 21/137) had hematologic malignancies, with the main types being breast cancer (25 cases, 18.25%) and lung cancer (24 cases, 17.52%). Among the cancer patients, 46 cases (33.58%) were asymptomatic, 81 cases (59.12%) had mild disease, 10 cases (7.30%) had severe infection, and 8 cases (5.84%) died. A total of 91 patients (66.42%) had been vaccinated, with 58 patients (42.34%) receiving three doses. Multivariate analysis showed that cerebral infarction and hypoproteinemia were risk factors for death from COVID-19 infection.
CONCLUSION
Cancer patients infected with SARS-CoV-2 Omicron typically exhibit mild disease manifestations, but some cancer patients infected with the Omicron variant might progress to severe illness, and even death, necessitating close monitoring and attention during the early stages of infection. Additionally, the presence of cerebral infarction and hypoproteinemia significantly increases the risk of death.
目的
分析2022年12月至2023年2月疫情高峰期间癌症住院患者感染新型冠状病毒奥密克戎变异株（SARS-CoV-2 Omicron）的临床特征及预后影响，为临床治疗及防控措施提供科学依据。
方法
对2022年12月至2023年2月新冠疫情期间感染奥密克戎变异株的癌症住院患者的临床特征、预后及疫苗接种情况进行回顾性分析。
结果
本研究共纳入137例癌症住院患者，中位年龄61岁，男性75例（54.74%）。主要症状为咳嗽（69例，50.36%）、咳痰（60例，43.80%）、发热（53例，39.69%）。胸部CT检查显示双侧肺炎47例（34.31%，47/137），胸腔积液24例（17.52%，24/137）。癌症患者中，116例（84.67%，116/137）为实体瘤，21例（15.33%，21/137）为血液系统恶性肿瘤，主要类型为乳腺癌（25例，18.25%）和肺癌（24例，17.52%）。癌症患者中，46例（33.58%）无症状，81例（59.12%）为轻症，10例（7.30%）为重症感染，8例（5.84%）死亡。共91例患者（66.42%）接种过疫苗，其中58例（42.34%）接种三剂。多因素分析显示，脑梗死和低蛋白血症是新冠感染死亡的危险因素。
结论
感染SARS-CoV-2 Omicron的癌症患者通常表现为轻症，但部分感染奥密克戎变异株的癌症患者可能进展为重症甚至死亡，感染早期需密切监测和关注。此外，脑梗死和低蛋白血症的存在显著增加死亡风险。
Zotero 插件